Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jyss Bio

Explore full profile

Single-use bioreactors and bioprocessing solutions for pharmaceuticals

Hangzhou, ChinaFounded 2014Biotech & Life Sciences
Valuation $100–250M Last recorded · 2022
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Jyss Bio and the history behind them.

About Jyss Bio

Zhejiang Jyss Bio-Engineering Co., Ltd. (Jyss Bio) is a high-tech enterprise founded in 2014 that localizes single-use bioreactors and assemblies for the biopharmaceutical industry in China. The company provides comprehensive technological solutions for the entire biopharmaceutical process, from research and development to industrialization. Its offerings cater to pharmaceutical production and R&D institutions involved with antibody drugs, vaccines, gene therapy, and cell therapy.

The company's product portfolio is centered around its core single-use bioreactors, which feature a patented, non-bubbling oxygen transfer mechanism designed for high efficiency and low shear force, enabling high-density cell cultivation. Beyond bioreactors, Jyss Bio develops and manufactures a wide array of single-use consumables and equipment for the entire bioprocess workflow. This includes products for cell culture, fluid management, purification, and filtration. Specific products include various bioreactor models (stirred, torrent, wave-mixed), magnetic mixing systems, sterile tube welders and sealers, chromatography systems, and single-use storage, mixing, and sampling bags.

Founded in Hangzhou, China, Jyss Bio operates multiple facilities, including GMP-compliant production workshops for consumables and bioreactors in Hangzhou and Huzhou, and a manufacturing base in Shanghai for downstream equipment. The company has received significant venture capital backing, completing Series A, B, and B+ funding rounds in 2021 and 2022 to expand production capacity and accelerate R&D. Key investors include Huatai International, CICC Capital, and Sinovac. As part of its growth, Jyss Bio has expanded its product lines into downstream purification with chromatography and ultrafiltration systems to provide integrated upstream and downstream solutions. The company was recognized for its contribution during the COVID-19 pandemic by CanSino Bio and has received industry awards such as the "2021 Best IVD and Life Science Enterprise Award".

Source: Dealroom company data

At a glance

Status
Operational
Founded
2014
Headquarters
Hangzhou, China
Employees
8
Open positions
None listed
Dealroom signal
25.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2022 $28M $110M Zhongjin Qiyuan Investment · CICC · Kexing Holdings · Huatai Securities ↗
SERIES BOther financing Jul 2021 $28M $110M Sherpa Invest · CMB International · CITIC Medical · Huatai Securities —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Jyss Bio website traffic

Latest recorded traffic for Jyss Bio is 1.9K monthly website visits, down 5% over the last three months. Jyss Bio's team grew 0% over the past year.

Latest monthly visits1.9K 3-month web change-5% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

  • Huatai Securities
  • CMB International Capital
  • Sherpa Invest
  • CMB International
  • CITIC Medical
  • Zhongjin Qiyuan Investment
  • CICC
  • Kexing Holdings
Employees 8 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Jyss Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Jyss Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.